Vote!
Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO‐ACT trial
The objective of the Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TO‐ACT) trial is to determine if endovascular thrombolysis improves the functional outcome of patients with a severe form of CVT.DesignThe TO‐ACT trial is a multicenter, prospective, randomized, open‐label, blinded endpoint trial. Patients are eligible if they have a radiologically proven CVT, a high probability of poor outcome (defined by presence of one or more of the following risk factors: mental status disorder, coma, intracranial hemorrhagic lesion, or thrombosis of the deep cerebral venous system), and if the responsible physician...
Published By: MedWorm/EatingDisorder - Tuesday, 21 February
